Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS)…
Articles by Margarida Maia, PhD
When a parent develops amyotrophic lateral sclerosis (ALS), adult children may face heavy emotional pressures and may have difficulty…
Cases of motor neuron diseases — including amyotrophic lateral sclerosis (ALS), the most common of these — are increasing…
Living in areas with a moderate amount of green space appears to reduce the likelihood of developing amyotrophic lateral…
The ALS Association has awarded $3 million to help expand access to specialized amyotrophic lateral sclerosis (ALS) care…
Higher blood levels of the pollutant hexachlorobenzene (HCB), once widely used as a pesticide and later restricted in many countries…
Caregivers across Canada can now access free professional mental health support specifically tailored to the unique challenges of caring for…
A pivotal Phase 3 clinical trial testing pridopidine, an experimental oral therapy being developed by Prilenia Therapeutics and…
Brooke Eby, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2022 at age 33, has been named the …
Tanabe Pharma Canada has announced the publication of a new book featuring personal letters from people living with…